3/18
03:06 pm
skye
Skye Bioscience, Inc. (OTCMKTS: SKYE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $12.00.
Neutral
Report
Skye Bioscience, Inc. (OTCMKTS: SKYE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $12.00.
3/4
07:00 am
skye
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Medium
Report
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
2/26
07:00 am
skye
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
High
Report
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
2/5
08:03 am
skye
Skye Bioscience, Inc. (OTCMKTS: SKYE) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.
High
Report
Skye Bioscience, Inc. (OTCMKTS: SKYE) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.